Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors: A Population-based Study Using SEER-Medicare Data

Conclusions: Patients with a pAID face a significantly higher risk of irAEs. Further research examining the clinical impact of these events on the patients’ oncological outcome and quality of life is urgently needed given our findings of significantly worse rates of adverse events.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Cutaneous Source Type: research